Tags

Type your tag names separated by a space and hit enter

Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis.
Scand J Rheumatol Suppl 1986; 61:242-5SJ

Abstract

Evidence from biochemical studies and from experimental animals indicates that abnormalities of essential fatty acid (EFA) and eicosanoid metabolism could lead to salivary and lacrimal gland atrophy and to immunological and cardio-vascular defects. Measurements of EFA levels in erythrocytes from patients with primary Sjögren's syndrome have shown that abnormalities are indeed present. Controlled clinical trials of supplementation with gamma-linolenic acid (GLA) as evening primrose oil (Efamol) in both primary Sjögren's syndrome and systemic sclerosis have given positive results. There are strong arguments to indicate that sophisticated manipulation of EFA metabolism may have a role to play, not only in Sjögren's syndrome but also in other rheumatological disorders.

Authors

No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

3296151

Citation

Horrobin, D F.. "Essential Fatty Acid and Prostaglandin Metabolism in Sjögren's Syndrome, Systemic Sclerosis and Rheumatoid Arthritis." Scandinavian Journal of Rheumatology. Supplement, vol. 61, 1986, pp. 242-5.
Horrobin DF. Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis. Scand J Rheumatol Suppl. 1986;61:242-5.
Horrobin, D. F. (1986). Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis. Scandinavian Journal of Rheumatology. Supplement, 61, pp. 242-5.
Horrobin DF. Essential Fatty Acid and Prostaglandin Metabolism in Sjögren's Syndrome, Systemic Sclerosis and Rheumatoid Arthritis. Scand J Rheumatol Suppl. 1986;61:242-5. PubMed PMID: 3296151.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Essential fatty acid and prostaglandin metabolism in Sjögren's syndrome, systemic sclerosis and rheumatoid arthritis. A1 - Horrobin,D F, PY - 1986/1/1/pubmed PY - 1986/1/1/medline PY - 1986/1/1/entrez SP - 242 EP - 5 JF - Scandinavian journal of rheumatology. Supplement JO - Scand. J. Rheumatol. Suppl. VL - 61 N2 - Evidence from biochemical studies and from experimental animals indicates that abnormalities of essential fatty acid (EFA) and eicosanoid metabolism could lead to salivary and lacrimal gland atrophy and to immunological and cardio-vascular defects. Measurements of EFA levels in erythrocytes from patients with primary Sjögren's syndrome have shown that abnormalities are indeed present. Controlled clinical trials of supplementation with gamma-linolenic acid (GLA) as evening primrose oil (Efamol) in both primary Sjögren's syndrome and systemic sclerosis have given positive results. There are strong arguments to indicate that sophisticated manipulation of EFA metabolism may have a role to play, not only in Sjögren's syndrome but also in other rheumatological disorders. SN - 0301-3847 UR - https://www.unboundmedicine.com/medline/citation/3296151/Essential_fatty_acid_and_prostaglandin_metabolism_in_Sjögren's_syndrome_systemic_sclerosis_and_rheumatoid_arthritis_ L2 - http://www.diseaseinfosearch.org/result/592 DB - PRIME DP - Unbound Medicine ER -